Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.

In spite of a high initial response rate of 60% –80% the vast majority of adult patients with acute myeloid leukemia (AML) still cannot be cured of the disease and ultimately die from recurrent and refractory leukemia. The development of new therapeutic approaches and of more effective drugs therefore seems warranted.